|October 21, 2002
|HEMISPHERX BIOPHARMA PROFILED ON TOP10MICROCAPSTOCKS.COM
| Website Focuses on Analysis and Tracking Micro Cap Companies in Various Industries
Philadelphia, PA, Monday, October 21, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, announced today that it has recently been profiled on Top10MicroCapStocks.com. Top10’s website is dedicated to analysis and tracking the top performing micro cap companies over various industries.
Dr. William Carter, President and CEO of Hemispherx Biopharma, stated that “the profiling of Hemispherx by Top10MicoCapStocks.com continues to validate the potential of the company as well is a welcomed recognition of the recent performance of the stock.”
A copy of the profile can be viewed in the Biotech section at http://www.top10microcapstocks.com.
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information, including the full text of the abstract described in this press release, please visit the company's Web site at www.hemispherx.net
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223
Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746
HEB's Web Site: www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company’s judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.